DOI QR코드

DOI QR Code

Postoperative radiotherapy for endometrial cancer

  • Choi, Eun Cheol (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Jin Hee (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kim, Ok Bae (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Byun, Sang Jun (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Park, Seung Gyu (Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine) ;
  • Kwon, Sang Hoon (Department of Gynecology and Obstetrics, Dongsan Medical Center, Keimyung University School of Medicine)
  • Received : 2012.06.25
  • Accepted : 2012.09.11
  • Published : 2012.09.30

Abstract

Purpose: To investigate the prognostic factors and effectiveness of postoperative radiotherapy alone for endometrial carcinoma. Materials and Methods: Sixty four patients with stage I-III endometrial cancer (EC) treated with postoperative radiotherapy alone between January 1989 and December 2008 at the Keimyung University Dongsan Medical Center were chosen for the present study. Typically, total hysterectomy, salpingo-oophorectomy and lymphadenectomy were performed on the patient's pelvis. Total dose from 50.4 Gy to 63 Gy was irradiated at pelvis or extended field. Thirteen patients were treated with Co-60 or Ir-192 intracavitary radiotherapy. Follow-up periods were from 7 to 270 months, with a median of 56 months. Results: Five year overall survival (OS) rate was 58.7%, respectively. Five year disease-free survival (DFS) rate was 59.2%, respectively. In univariate analysis for OS and DFS, stage, menopausal age, type of operation, serosal invasion, and lymph node involvement were found to be statistically significant. Histologic type was marginally significant. In multivariate analysis for OS and DFS, stage, types of operation, histologic type were also found to be statistically significant. Treatment failure occurred in 14 patients. The main pattern of failure was found to be distant metastasis. Time to distant metastasis was from 3 to 86 months (median, 12 months). There were no grade 3 or 4 complications. Conclusion: Stage, types of operation, and histologic type could be the predictive prognostic factors in patients. We contemplated postoperative radiation as effective and safe treatment method for EC. Additional treatment would be needed to reduce distant metastasis.

References

  1. National Cancer Information Center (Korea). Cancer incidence [Internet]. Goyang (KR): National Cancer Information Center; c2011 [cited 2012 Sep 15]. Available from: http://www.cancer.go.kr/ncic/cics_f/01/011/index.html.
  2. Lee CM, Szabo A, Shrieve DC, et al. Descriptive nomograms of adjuvant radiotherapy use and patterns of care analysis for stage I and II endometrial adenocarcinoma: a surveillance, epidemiology, and end results population study. Cancer 2007;110:2092-100. https://doi.org/10.1002/cncr.22997
  3. ASTEC/EN.5 Study Group, Blake P, Swart AM, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137-46. https://doi.org/10.1016/S0140-6736(08)61767-5
  4. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-11. https://doi.org/10.1016/S0140-6736(00)02139-5
  5. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: longterm outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-8. https://doi.org/10.1016/j.ijrobp.2005.03.007
  6. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744-51. https://doi.org/10.1016/j.ygyno.2003.11.048
  7. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-27.
  8. Scotti V, Borghesi S, Meattini I, et al. Postoperative radiotherapy in stage I/II endometrial cancer: retrospective analysis of 883 patients treated at the University of Florence. Int J Gynecol Cancer 2010;20:1540-8.
  9. Eiriksson L, Cuartero J, Steed H, et al. Assessment of outcomes in surgically staged I/II endometrial adenocarcinoma patients treated with postoperative vaginal vault radiotherapy only. Int J Gynecol Cancer 2010;20:1356-62.
  10. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006;24:36-44. https://doi.org/10.1200/JCO.2004.00.7617
  11. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006;95:266-71. https://doi.org/10.1038/sj.bjc.6603279
  12. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-33. https://doi.org/10.1016/j.ygyno.2007.09.029
  13. Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006;103:155-9. https://doi.org/10.1016/j.ygyno.2006.02.007
  14. Hogberg T, Rosenberg P, Kristensen G, et al. A randomized phase-III study on adjuvant treatment with radiation (RT) $\pm$ chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract]. J Clin Oncol 2007;25(18S):5503.
  15. US National Institute of Health. ClinicalTrials.gov [Internet]. Bethesda, MD: US National Institute of Health; c2012 [cited 2012 Sep 15]. Available from: http://clinicaltrials.gov/ct2/ home.
  16. Irwin C, Levin W, Fyles A, Pintilie M, Manchul L, Kirkbride P. The role of adjuvant radiotherapy in carcinoma of the endometrium-results in 550 patients with pathologic stage I disease. Gynecol Oncol 1998;70:247-54. https://doi.org/10.1006/gyno.1998.5064
  17. Uharcek P. Prognostic factors in endometrial carcinoma. J Obstet Gynaecol Res 2008;34:776-83. https://doi.org/10.1111/j.1447-0756.2008.00796.x
  18. Yalman D, Ozsaran Z, Anacak Y, et al. Postoperative radiotherapy in endometrial carcinoma: analysis of prognostic factors in 440 cases. Eur J Gynaecol Oncol 2000;21:311-5.
  19. Yoney A, Yildirim C, Bati Y, Unsal M. Low risk stage I endometrial carcinoma: prognostic factors and outcomes. Indian J Cancer 2011;48:204-10. https://doi.org/10.4103/0019-509X.82895
  20. Pessini SA, Zettler CG, Wender MC, Pellanda LC, Silveira GP. Survival and prognostic factors of patients treated for stage I to stage III endometrial carcinoma in a reference cancer center in Southern Brazil. Eur J Gynaecol Oncol 2007;28:48-50.
  21. Li J, Kong WM. Prognostic factors of stage III endometrial carcinoma. Zhonghua Yi Xue Za Zhi 2009;89:198-200.
  22. Grodin JM, Siiteri PK, MacDonald PC. Source of estrogen production in postmenopausal women. J Clin Endocrinol Metab 1973;36:207-14. https://doi.org/10.1210/jcem-36-2-207
  23. Trabert B, Wentzensen N, Yang HP, et al. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2012 May 3 [Epub]. http://dx.doi.org/10.1002/ijc.27623.